This Substack is reader-supported. To receive new posts and support my work, consider becoming a free or paid subscriber.
The Event. Two things landed today. First, an 8-K disclosing a Loan and Security Agreement dated August 12, 2026 with Innovatus Life Sciences Lending Fund I: $55M funded at close (Term A), $25M milestone-gated (Term B), $20M discretionary (Term C) — up to $100M total, maturing August 14, 2031. Proceeds repay the existing Ankura facility in full. Second, a special dividend of contingent value rights (CVRs), one per share, record date September 30, 2026, distribution October 7, 2026, entitling holders to net cash proceeds from any sale or license of the leftover biosimilar patents, cell lines and the existing Pfizer royalty stream.
The Reaction. The stock closed at $1.15, down 20.7% from the $1.45 print on August 5 when I wrote that the runway “no longer extends comfortably past the readout into a negotiating position.” The market has been pricing exactly that anxiety. Today’s filings are management’s answer — and they chose debt and a scrip dividend over equity.
The Reality. This is not free money. It is expensive, covenanted, IP-secured money that arrives roughly seven weeks before a 72-patient binary. But it means the early-October readout will not be preceded by a dilutive raise at $1.15, which is materially better than the alternative I had penciled in.
The Receipts
The loan: $55M funded, priced like a company with a coin flip in front of it. Interest accrues at the Basic Rate = the greater of Prime or 6.75%, plus 4.15%. At today’s Prime that puts the coupon somewhere in the 11.5–12% zone, floating. On top: a 1.50% Facility Fee on each draw, a 4.00% Final Fee on the aggregate principal funded (payable at maturity, acceleration, or prepayment), and a Prepayment Fee starting at 5.00% in year one and stepping down 4% / 3% / 0% by year four. Interest-only for 36 months from the Term A funding date, extendable to 48 months if the Term B milestone hits, with amortization beginning September 1, 2029 at the earliest.
The implication: Call it ~$6.5M/year of cash interest on $55M — a real, permanent drag on a company running ~$30–33M/quarter in continuing-ops burn. Coherus swapped the $38.7M Ankura term loan for a bigger, longer, pricier facility. It bought time, not economics.
Term B is gated on commercial execution, not on data. The $25M Term B Loan requires Trailing Three Month Revenue of ≥$35.0M on or prior to March 31, 2028 and a pro-forma debt-to-market-cap ratio below 25%. Draw window: September 1, 2027 through April 30, 2028. There’s a $750,000 non-utilization fee if they hit the milestone and then don’t draw without notifying the lender.
Why it matters: $35M in a trailing three-month window is roughly $140M annualized. LOQTORZI did $13.6M in Q2 2026. Getting to $35M/quarter by early 2028 requires either a label expansion beyond NPC or a genuinely different commercial footprint. That milestone is a stretch goal, not a base case — which means the practical facility size is $55M, and the second $25M should be modeled at low probability.
The covenants are the part to read twice. There is a Liquidity Covenant (Section 6.13, terms redacted on Schedule 6.13) enforced at all times from funding. There’s an IP Security Agreement granting Innovatus a first-priority perfected lien across the collateral — patents, trademarks, trade secrets, license rights. There’s a Delisting event of default (Section 8.13) if CHRS falls off Nasdaq without immediately relisting elsewhere. And there’s an FDA Action default clause (Section 8.11) covering warning letters, recalls and Form 483 remediation failures.
The implication: I flagged the old Ankura minimum-cash covenant as “a quiet killer — running the balance sheet too low triggers default before bankruptcy is mathematically required.” That killer didn’t go away; it got a new landlord with a lien on the intellectual property. At $1.15 and roughly 154.5M shares, the market cap is about $178M. A bad October readout is a genuine delisting-risk conversation, and the loan documents now make delisting a credit event.
One meaningful protection Coherus negotiated. Section 8.2(a) carves out going-concern qualifications: audited statements for fiscal 2028 and later containing a going-concern flag do not constitute an Event of Default before delivery. And the lender explicitly permits Permitted Exclusive Out-Licenses of ex-US regional rights to tagmokitug, casdozokitug and CHS-1000 — meaning a partnership deal on the pipeline is contractually pre-blessed rather than blocked.
Follow the money: Innovatus is a life-sciences specialty lender. They underwrote $55M against a company with a 72-patient randomized Phase 2 reading out in seven weeks, and they took an IP lien and a liquidity covenant to do it. That’s not a vote of confidence in the data — it’s a collateralized bet that the LOQTORZI franchise plus the biosimilar residuals cover the loan if the science doesn’t. Read it as credit underwriting, not as clinical endorsement.
The CVR: a scrip dividend on assets nobody was valuing. One CVR per share, record date September 30, distribution October 7, expiring October 7, 2028. Underlying: six issued biosimilar formulation patents (adalimumab and aflibercept), cell lines, lab notebooks, regulatory filings, and royalties under the October 21, 2019 License and Settlement Agreement with Pfizer. Non-transferable, not listed, no interest, no voting rights, no equity interest. An investment bank has been retained to run the sale process.
Reality check: Payments are net proceeds — gross cash minus taxes, transaction costs, banker fees, maintenance costs, indemnification losses, and any escrow holdbacks. And critically: “no CVR Payment shall be made to the extent that the Company determines in its sole discretion that all or any portion of the CVR Payments are prohibited by the terms and conditions of” the Innovatus loan. The CVR agreement itself concedes the possibility “is highly speculative” and that the rights could “expire without payment.” This is a lottery ticket stapled to your share certificate — genuinely free optionality, but the loan sits senior to it and the company disclaims any fiduciary duty to CVR holders.
The Scientific Reality Check
Nothing today touches the science. The casdozokitug randomized Phase 2 in 1L HCC — casdozo + toripalimab + bevacizumab at two doses versus tori/bev alone, ~72 patients, 1:1:1, blinded independent central review — is still enrolled, still maturing, still due in early October 2026. The bar remains what it always was: does the 17.2% complete-response rate from the 29-patient single-arm cohort survive randomization against a control arm, when the IMbrave150 historical CR benchmark for atezo/bev is roughly 7–8%?
What today’s news does change is the shape of the outcome distribution. Before, a mediocre readout meant a raise at a distressed price. Now, a mediocre readout means a company carrying $55M of secured, IP-collateralized debt at ~12% into a period where it still needs capital — and the equity sits behind that debt. Leverage cuts both ways: it magnifies the upside on a clean win because there’s no dilution between here and the data, and it magnifies the downside on a miss because the capital structure got heavier while the enterprise value got lighter.
The Permitted Exclusive Out-License carve-out is the tell I’d watch. Innovatus specifically pre-approved ex-US regional licensing of all three pipeline assets. Lenders write that language when they expect the borrower may need to monetize partial rights to service the loan. It’s also, more charitably, the mechanism by which a positive October readout converts into non-dilutive cash — an ex-US casdozokitug deal after good HCC data would be the cleanest financing Coherus could execute.
Updated Catalyst Calendar
Early October 2026 — Casdozokitug randomized Phase 2 in 1L uHCC. Still THE BIG ONE. ±50% remains the base case for the stock reaction.
September 29, 2026 — Expected ex-dividend date for the CVR. Shares purchased on or after September 30 do not carry the CVR.
September 30, 2026 — CVR record date. Also the UDENYCA Earnout #1 trigger date ($37.5M if Intas/Accord net sales hit $300M for the four trailing quarters). The Q2 10-Q already stated Intas-reported revenues did not meet either threshold. Still not a number to model.
October 7, 2026 — CVR distribution date; two-year clock starts.
2H 2026 — Tagmokitug Phase 1b data in 2L HNSCC and upper GI; the fully-enrolled Phase 1b/2a in 4L+ MSS colorectal.
September 1, 2027 – April 30, 2028 — Term B draw window, gated on $35M trailing-three-month revenue.
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.